Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) elects Randle House as VP of Pharmacy Operations. In the newly appointed position, House will head the company’s distribution and operations team, with responsibility for patent-pending proprietary drug formulations and other novel pharmaceutical solutions. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) shares after opening at $6.92 moved to $7.98 on last trade day and at the end of the day closed at $7.92. Company price to sales ratio in past twelve months was calculated as 8866.41 and price to cash ratio as 3.93. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) showed a negative weekly performance of -4.50%.
WH Ireland began coverage on shares of Caledonia-Mining (LON:CMCL) in a report issued on Monday, AnalystRatingsNetwork reports. The firm issued a buy rating and a GBX 100 ($1.67) target price on the stock. Caledonia Investments plc (LON:CLDN) shares fell -0.46% in last trading session and ended the day on $1,940.00. CLDN return on equity ratio is recorded as 83.40% and its return on assets is -105.30%.
BIND Therapeutics Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM announced it will report fourth quarter and year ended December 31 2013 financial results on Tuesday March 25 2014. BIND’s management team will host a conference call and audio webcast at 8:30 a.m. Eastern Time on Tuesday March 25 2014 to discuss the quarterly results and recent business developments. BIND Therapeutics Inc (NASDAQ:BIND) shares moved down -7.90% in last trading session and was closed at $12.00, while trading in range of $ 11.80 – 12.97. BIND Therapeutics Inc (NASDAQ:BIND) year to date (YTD) performance is -20.48%.
Five Prime Therapeutics (NASDAQ:FPRX) had its target price boosted by Jefferies Group from $20.00 to $28.00 in a report issued on Tuesday, American Banking and Market News reports. Five Prime Therapeutics Inc (NASDAQ:FPRX) weekly performance is 19.33%. On last trading day company shares ended up $21.36. Five Prime Therapeutics Inc (NASDAQ:FPRX) distance from 50-day simple moving average (SMA50) is 28.34%. Analysts mean target price for the company is $21.33.